cancertope

cancertope identifies cancer-specific epitopes and neoepitopes from cancer genomes to support personalized cancer immunotherapy and vaccine design.

Key Features:

• Cancer-specific neoepitope database: Contains neoepitopes derived from the genomes of 905 cancer cell lines.
• Epitope types: Includes B-cell, CD8+ T-cell, HLA class I, and HLA class II epitopes.
• Vaccine antigen coverage: Covers 60 cancer-specific vaccine antigens.
• Partially personalized prediction: Predicts potential neoepitopes from a user-supplied cancer genome.
• Customizable analysis: Allows tailoring of predictions to specific aspects of a cancer genome.
• Fully personalized identification: Identifies neoepitopes from both cancerous and healthy cells of a specific patient through comparative analysis.
• Epitope screening: Screens epitopes against the human reference proteome.

Scientific Applications:

• Personalized immunotherapy and vaccine design: Identification of neoepitopes to inform development of patient-tailored cancer vaccines and immunotherapies.
• Neoantigen discovery from cell lines: Use of the 905 cancer cell line-derived neoepitope database to discover candidate neoantigens.
• Patient-specific neoantigen identification: Detection of patient-unique neoepitopes by comparing tumor and normal genomes.
• Vaccine antigen selection: Prioritization of cancer-specific vaccine antigens from the curated set of 60 antigens.
• Epitope target validation: Screening against the human reference proteome to identify relevant targets.

Methodology:

Derives neoepitopes from cancer cell line genomes (905 cell lines), predicts neoepitopes from user-supplied cancer genomes, identifies patient-specific neoepitopes by comparing cancerous and healthy genomes, and screens epitopes against the human reference proteome.